Hello,
I'm an APRN working in a free-standing pediatric hospital and working to improve/update our hospital guidelines and standard work surrounding our nPEP patients (specifically as it relates to Sexual Assault).
With dolutegravir recently receiving approval for patients down to 4 weeks of age, does anyone foresee (or currently already practice) that children aged less than 12 years could utilize dolutegravir (instead of raltegravir which is BID or Kaletra which tastes poorly) safety for their 28 day course of nPEP (in conjunction with appropriate NRTI backbone as per the guidelines)?
With kids it is sometimes difficult to be on the cutting edge and these changes sometimes trickle down while we wait for updated guidelines from the CDC, etc.
Thanks in advance for any help or opinions!
------------------------------
Diane Petrie, FNP-BC, AAHIVS
Kansas City, MO
------------------------------